TY - CHAP M1 - Book, Section TI - Systemic Lupus Erythematosus A1 - Manno, Rebecca L. A1 - Yazdany, Jinoos A1 - Tarrant, Teresa K. A1 - Kwan, Mildred A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Systemic Lupus ErythematosusBelimumab is FDA-approved for the treatment of active lupus nephritis.Anifrolumab, a type 1 interferon receptor antagonist, is FDA-approved to treat non-renal lupus that has not responded to standard therapies.Voclosporin, a novel calcineurin inhibitor, is FDA-approved to treat active lupus nephritis when used in combination with mycophenolate mofetil.Evidence increasingly suggests that renal response can be enhanced with combination immunosuppressive therapy.Morand EF et al; TULIP-2 Trial Investigators. N Engl J Med. [PMID: 31851795]Rovin BH et al. Lancet. [PMID: 33971155] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193125554 ER -